Press Releases

All Releases
View Summary Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Safety Trial Evaluating FPA144 in Gastric Cancer in Japan in Preparation for Future Global Late-Stage Development
Monday, July 17, 2017
PDF 13.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Lewis T. "Rusty" Williams Plans to Transition from CEO to Executive Chairman of the Board in 2018
Wednesday, June 21, 2017
PDF 13.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference
Monday, June 5, 2017
PDF 9.3 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting
Sunday, June 4, 2017
PDF 15.8 KB Add to Briefcase
View Summary Five Prime Therapeutics Presents Updated Data From Phase 1 Trial of Single-Agent FPA144 at 2017 ASCO Annual Meeting
Saturday, June 3, 2017
PDF 64.3 KB Add to Briefcase
View Summary Five Prime Welcomes Garry Nicholson to Board of Directors
Monday, May 15, 2017
PDF 10.9 KB Add to Briefcase
View Summary Five Prime Announces First Quarter 2017 Results and Provides Business Update
Thursday, May 4, 2017
PDF 28.5 KB Add to Briefcase
View Summary Five Prime to Present Clinical Data at 2017 ASCO Annual Meeting
Thursday, April 20, 2017
PDF 11.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce First Quarter 2017 Financial Results and Host Conference Call on May 4
Thursday, April 20, 2017
PDF 9.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis (PVNS)
Monday, April 10, 2017
PDF 12.0 KB Add to Briefcase
View Summary Five Prime Presents Data on Unique Immuno-Oncology Discovery Research at the 2017 AACR Annual Meeting
Monday, April 3, 2017
PDF 14.5 KB Add to Briefcase
View Summary Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting
Monday, April 3, 2017
PDF 12.6 KB Add to Briefcase
View Summary Five Prime Presents Preclinical Research Data on Novel Tetravalent Anti-GITR Antibody at 2017 AACR Annual Meeting
Sunday, April 2, 2017
PDF 12.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Executive Changes
Monday, March 20, 2017
PDF 12.1 KB Add to Briefcase
View Summary Five Prime Announces Fourth Quarter and Full Year 2016 Financial Results
Thursday, February 23, 2017
PDF 30.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call on February 23
Thursday, February 9, 2017
PDF 9.4 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
Wednesday, February 8, 2017
PDF 10.0 KB Add to Briefcase
View Summary Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting
Wednesday, February 8, 2017
PDF 11.9 KB Add to Briefcase
View Summary European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis (PVNS)
Tuesday, January 24, 2017
PDF 12.0 KB Add to Briefcase
View Summary Five Prime Therapeutics and Bristol-Myers Squibb Extend Research Term in Collaboration to Discover Novel Immuno-Oncology Therapies for Three Immune Checkpoint Pathways
Wednesday, January 4, 2017
PDF 13.1 KB Add to Briefcase
Showing 1-20 of 173 Page: 1 2 3 4 5 ... 9  Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
29.01
Change (%)
0.00
Volume
N/A

Data as of 4:00 PM ET on Thursday, July 20, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.